Clinical Trial Update: Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating pralatrexate for advanced or metastatic relapsed transitional cell carcinoma of the urinary bladder has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Transitional Cell Carcinoma of the Bladder

Drugs mentioned

• Pralatrexate (pralatrexate)

Snippet

Sponsor: Acrotech Biopharma Inc. | Conditions: Carcinoma, Transitional Cell, Bladder Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-07-17